Financial Highlights for Q1FY23 Vs Q4FY22:
• Reported total Revenue at Rs 1298.38 lakhs in Q1FY23 Vs Rs
1019.32 in Q4FY22 which has grown by 27.38%.
• Company reported EBITDA at Rs 519.44 lakhs in Q1FY23 Vs Rs.
376.70 lakhs in Q4FY22 which has increased by 38%.
• On QoQ Basis Company’s Profit After Tax (PAT) has grown by 50% at
Rs. 368.18 lakhs in Q1FY23 Vs Rs 246.24 lakhs in Q4FY22.
Prevest DenPro Limited today announced that the U.S. Food and Drug Administration (FDA) has approved four of its products falling in the category of Dental Cavity Liners. Prevest DenPro Limited is the 1st Indian dental manufacturer who has received USFDA approvals for its products. The products are which have been recently approved in the category of Cavity Liners are CalUltra, Cal LC, Apacal ART and Calcigel. All these products are calcium hydroxide base cavity liners highly useful for endodontic treatment worldwide.
With the approval of these products our product portfolio has widened and we have better marketing prospects in the USA market. As an organization committed to expand its market globally, this approval will enable us to serve the international market especially US Market with a bigger product portfolio. The approval is also an endorsement of our commitment to comply with global manufacturing standards and regulations. Prevest DenPro Limited is committed to continue its efforts in developing newer innovative products and expanding business globally to make it a truly a world class dental company.
Prevest DenPro announces robust 9MFY22 results, reports PAT of Rs 9.11 Cr.
New Delhi: Prevest Denpro Limited (BSE Code: 543363), a leading homegrown manufacturer of dental materials, has announced its 9 months results for Fiscal Year 2022.
Jammu based Prevest DenPro was listed on BSE SME platform in September 2021. Established in 1999, the company has a successful track record of more than two decades in manufacturing over 100 dental products with export to more than 80 countries worldwide, which contributes 60% to the revenue.
Financial Highlights for the 9MFY2022:
* Total Revenue of Rs 29.54 crores
* EBITDA of Rs 12.91 crores
* Profit After Tax of Rs 9.11 crores
* EPS of Rs 7.59 per share
Financial Highlights for Q3FY2022:
* Total Revenue of Rs 11.79 crores
* EBITDA of Rs 5.26 crores
* Profit After Tax of Rs 3.75 crores
* EPS of Rs 3.13 per share
Commenting on the company's financial performance, Mr Atul Modi, Chairman and Managing Director of Prevest DenProsaid, "with our continuous efforts in the development of new products, aggressive marketing and brand promotion, our company continues to report strong financials with a healthy topline and bottom line.
The company has a strong network of more than 90 international dealers in more than 80 countries of Europe, South America, Middle East, Africa and Asia. We are making continuous efforts to spread our business in other countries.
The company also obtained USFDA approval for their dental cements products and expects to receive approval for a few more products very soon. The company has also received MDSAP Certification and now it can export the products to Canada and Brazil. We expect to sell our products in USA, Canada, and Brazil in the near future.
The company has obtained Saudi FDA approval and has already started exporting to Saudi Arabia where the products have been well accepted and we aim for a sizeable business coming from Saudi Arabia.
The company has undertaken expansion or modernization of existing factory, setting up a state-of-the-art research center, diversification into manufacture of oral hygiene, oral care products, and biomaterials such as bone grafting materials and membranes which will immensely contribute to the revenue of the company and enhance its market position.”
For media queries, please contact
Harday Gupta | 8103101801 | [email protected]